Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 7/20 | 0.53 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.53 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.53 |
| ▸ | PPARG | P37231 | 1/20 | 0.53 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.53 |
| ▸ | CXCL8 | P10145 | 4/20 | 0.40 |
| ▸ | FABP3 | P05413 | 1/20 | 0.36 |
| ▸ | FABP4 | P15090 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | DHODH | Q02127 | 2/20 | 0.34 |
| ▸ | PTGES | O14684 | 1/20 | 0.34 |
| ▸ | CLCN2 | P51788 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2880886 | 0.92 | PTGS2 (0.52) | PTGS2PTGS1ABCB11PPARGNR1I3 | |
| SCHEMBL2888391 | 0.82 | PTGS2 (0.48) | PTGS2PTGS1ABCB11PPARGNR1I3 | |
| SCHEMBL27595572 | 0.81 | PTGS2 (0.64) | PTGS2PTGS1ABCB11PPARGNR1I3 | |
| SCHEMBL7131340 | 0.76 | PTGS2 (0.67) | PTGS2PTGS1ABCB11PPARGNR1I3 | |
| SCHEMBL3884087 | 0.75 | PTGS2 (0.68) | PTGS2PTGS1ABCB11PPARGNR1I3 | |
| SCHEMBL2886958 | 0.74 | PTGS2 (0.66) | PTGS2PTGS1ABCB11PPARGNR1I3 | |
| SCHEMBL577022 | 0.71 | PTGS2 (0.45) | PTGS2PTGS1ABCB11PPARGNR1I3 | |
| Lumiracoxib SCHEMBL4479 | 0.70 | PTGS2 (1.00) | PTGS2PTGS1ABCB11PPARGNR1I3 | |
| Lumiracoxib SCHEMBL29377334 | 0.70 | PTGS2 (1.00) | PTGS2PTGS1ABCB11PPARGNR1I3 | |
| Lumiracoxib SCHEMBL29475008 | 0.70 | PTGS2 (1.00) | PTGS2PTGS1ABCB11PPARGNR1I3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8541398-B2 | Hydrogen sulfide derivatives of non-steroidal anti-inflammatory drugs | ANTIBE THERAPEUTICS INC. (CA) | 2013-09-24 | — | — | US | disclosed |
| EP-2057139-B1 | HYDROGEN SULFIDE DERIVATIVES OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS | ANTIBE THERAPEUTICS INC (US) | 2013-09-04 | — | — | EP | disclosed |
| US-8314140-B2 | 4-hydroxythiobenzamide derivatives of drugs | ANTIBE THERAPEUTICS INC. (CA) | 2012-11-20 | — | — | US | disclosed |
| US-20100210607-A1 | HYDROGEN SULFIDE DERIVATIVES OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS | ANTIBE THERAPEUTICS INC. (CA) | 2010-08-19 | — | — | US | disclosed |
| US-7741359-B2 | Hydrogen sulfide derivatives of non-steroidal anti-inflammatory drugs | ANTIBE THERAPEUTICS INC. (CA) | 2010-06-22 | — | — | US | disclosed |
| US-20090306412-A1 | 4-HYDROXYTHIOBENZAMIDE DERIVATIVES OF DRUGS | ANTIBE THERAPEUTICS INC. (CA) | 2009-12-10 | — | — | US | disclosed |
| EP-2057139-A1 | HYDROGEN SULFIDE DERIVATIVES OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS | Antibe Therapeutics Inc. (US) | 2009-05-13 | — | — | EP | disclosed |
| EP-2041108-A1 | 4-HYDROXYTHIOBENZAMIDE DERIVATIVES OF DRUGS | Antibe Therapeutics Inc. (US) | 2009-04-01 | — | — | EP | disclosed |
| WO-2008009118-A1 | 4-HYDROXYTHIOBENZAMIDE DERIVATIVES OF DRUGS | ANTIBE THERAPEUTICS INC. (CA) | 2008-01-24 | — | — | WO | disclosed |
| WO-2008009127-A1 | HYDROGEN SULFIDE DERIVATIVES OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS | ANTIBE THERAPEUTICS INC. (CA) | 2008-01-24 | — | — | WO | disclosed |
| US-20080004245-A1 | HYDROGEN SULFIDE DERIVATIVES OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS | ANTIBE THERAPEUTICS INC. (CA) | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306412-A1 | 4-HYDROXYTHIOBENZAMIDE DERIVATIVES OF DRUGS | HRH4, HRH2, HNMT | PTGS2 125/4885PTGS1 115/4885ABCB11 81/4885 |
| US-20080004245-A1 | HYDROGEN SULFIDE DERIVATIVES OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS | PTGS1, HPGDS, PTGES | PTGS2 4/4885PTGS1 1/4885ABCB11 1085/4885 |
| US-20100210607-A1 | HYDROGEN SULFIDE DERIVATIVES OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS | PTGS1, HPGDS, PTGES | PTGS2 4/4885PTGS1 1/4885ABCB11 1085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.